Educational guide
Therapeutic peptides: current applications and future ...
Henninot, A., Collins, J. C. & Nuss, J. M. The current state of peptide drug discovery: back to the future? J. Med Chem. 61 , 1382–1414 (2018). Article CAS PubMed Google Scholar Craik, D. J., Fairlie, D. P., Liras, S. & Price, D. The future of peptide-based dr
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Henninot, A., Collins, J. C. & Nuss, J. M. The current state of peptide drug discovery: back to the future? J. Med Chem. 61, 1382–1414 (2018).
Craik, D. J., Fairlie, D. P., Liras, S. & Price, D. The future of peptide-based drugs. Chem. Biol. Drug Des. 81, 136–147 (2013).
Bliss, M. Banting’s, Best’s, and Collip’s accounts of the discovery of insulin. Bull. Hist. Med 56, 554–568 (1982).
Scott, D. A. & Best, C. H. The preparation of insulin. Ind. Eng. Chem. 17, 238–240 (1925).
Mathieu, C., Gillard, P. & Benhalima, K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nat. Rev. Endocrinol. 13, 385–399 (2017).
Zaykov, A. N., Mayer, J. P. & DiMarchi, R. D. Pursuit of a perfect insulin. Nat. Rev. Drug Disco. 15, 425–439 (2016).
Lau, J. L. & Dunn, M. K. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg. Med Chem. 26, 2700–2707 (2018).
Sawyer, W. H. & Manning, M. Synthetic analogs of oxytocin and the vasopressins. Annu Rev. Pharm. 13, 1–17 (1973).
Spiegelman, A. R. Synthetic vasopressin and diabetes insipidus. JAMA 187, 1035 (1964).
Keen, H. et al. Human insulin produced by recombinant DNA technology: safety and hypoglycaemic potency in healthy men. Lancet 2, 398–401 (1980).
Johnson, I. S. Human insulin from recombinant DNA technology. Science 219, 632–637 (1983).
Machado, E. S. et al. Successful desensitization of enfuvirtide after a first attempt failure. AIDS 20, 2130–2131 (2006).
de Castro, N. et al. Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial. AIDS Res Ther. 13, 17 (2016).
Bourinet, E. & Zamponi, G. W. Block of voltage-gated calcium channels by peptide toxins. Neuropharmacology 127, 109–115 (2017).
Deer, T. R., Pope, J. E., Hanes, M. C. & McDowell, G. C. Intrathecal therapy for chronic pain: a review of morphine and ziconotide as firstline options. Pain. Med 20, 784–798 (2019).
Drucker, D. J. The discovery of GLP-2 and development of teduglutide for short bowel syndrome. ACS Pharm. Transl. Sci. 2, 134–142 (2019).
Burness, C. B. & McCormack, P. L. Teduglutide: a review of its use in the treatment of patients with short bowel syndrome. Drugs 73, 935–947 (2013).
Malm-Erjefalt, M. et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab. disposition: Biol. fate Chem. 38, 1944–1953 (2010).
Hamad, F. et al. Systematic review of glucagon like peptide one receptor agonist liraglutide for subjects with heart failure with reduced left ventricular ejection fraction. Curr Diabetes Rev, 17, 280–292 (2021).
Fisher, E., Pavlenko, K., Vlasov, A. & Ramenskaya, G. Peptide-based therapeutics for oncology. Pharm. Med. 33, 9–20 (2019).
Iyengar, S., Ossipov, M. H. & Johnson, K. W. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain 158, 543–559 (2017).
Sloan, L. A. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects. J. Diabetes 11, 938–948 (2019).
Peterson, S. C. & Barry, A. R. Effect of glucagon-like peptide-1 receptor agonists on all-cause mortality and cardiovascular outcomes: a meta-analysis. Curr. Diabetes Rev. 14, 273–279 (2018).
Torres, M. D. T., Sothiselvam, S., Lu, T. K. & de la Fuente-Nunez, C. Peptide design principles for antimicrobial applications. J. Mol. Biol. 431, 3547–3567 (2019).
Research, T. M. Global IndustryAnalysis, Size, Share, Growth, Trends and Forecast. Pept. Mark. 2016–2024, (2016).
Peptide Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012−2018. Transparency Market Research: Albany. NY, (2012).
group, N. Top 200 Pharmaceuticals by Retail Sales in 2019. University of Arizona, (2020).
Muttenthaler, M., King, G. F., Adams, D. J. & Alewood, P. F. Trends in peptide drug discovery. Nat. Rev. Drug Disco. 20, 309–325 (2021).
Fosgerau, K. & Hoffmann, T. Peptide therapeutics: current status and future directions. Drug Disco. Today 20, 122–128 (2015).
Giordano, C., Marchio, M., Timofeeva, E. & Biagini, G. Neuroactive peptides as putative mediators of antiepileptic ketogenic diets. Front Neurol. 5, 63 (2014).
Davda, J. et al. Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. J. Immunother. Cancer. 7, 105 (2019).
Waldmann, H. Human monoclonal antibodies: the residual challenge of antibody immunogenicity. Methods Mol. Biol. 1060, 1–8 (2014).
Imai, K. & Takaoka, A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6, 714–727 (2006).
Smith, A. J. New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics. J. Biomol. Screen 20, 437–453 (2015).
Lawson, A. D. Antibody-enabled small-molecule drug discovery. Nat. Rev. Drug Disco. 11, 519–525 (2012).
Li, X. F., Liu, C. F. & Rao, G. W. Monoclonal antibodies, small molecule inhibitors and antibody-drug conjugates as HER2 inhibitors. Curr. Med Chem. 28, 3339–3360 (2021).
Smith, M. C. & Gestwicki, J. E. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Expert Rev. Mol. Med 14, e16 (2012).
Petta, I. et al. Modulation of protein-protein interactions for the development of novel therapeutics. Mol. Ther. 24, 707–718 (2016).
Faivre, S., Demetri, G., Sargent, W. & Raymond, E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Disco. 6, 734–745 (2007).
White, P. T. & Cohen, M. S. The discovery and development of sorafenib for the treatment of thyroid cancer. Expert Opin. Drug Dis. 10, 427–439 (2015).
Wilhelm, S. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 6, 126–126 (2007). (vol 5, pg 835, 2006).
Vuong, H. G. et al. Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysis. Head. Neck 41, 2823–2829 (2019).
Escudier, B., Worden, F. & Kudo, M. Sorafenib: key lessons from over 10 years of experience. Expert Rev. anticancer Ther. 19, 177–189 (2019).
Randrup Hansen, C. et al. Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma. Int J Mol Sci. 18, 461(2017).
Sehdev, S. Sunitinib toxicity management - a practical approach. Can. Urol. Assoc. J. 10, S248–S251 (2016).
Ferrara, N. & Adamis, A. P. Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Disco. 15, 385–403 (2016).
Diao, L. & Meibohm, B. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clin. pharmacokinetics 52, 855–868 (2013).
Del Olmo-Garcia, M. I. & Merino-Torres, J. F. GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes. J. Diabetes Res 2018, 4020492 (2018).
Reed, J., Bain, S. & Kanamarlapudi, V. Recent advances in understanding the role of glucagon-like peptide 1. F1000Res. 9, F1000 Faculty Rev-239 (2020).
Jones, L. H. & Price, D. A. Medicinal chemistry of glucagon-like peptide receptor agonists. Prog. Med Chem. 52, 45–96 (2013).
Alavi, S. E., Cabot, P. J. & Moyle, P. M. Glucagon-like peptide-1 receptor agonists and strategies to improve their efficiency. Mol. Pharm. 16, 2278–2295 (2019).
Marshall, J. C. & Kelch, R. P. Gonadotropin-releasing hormone: role of pulsatile secretion in the regulation of reproduction. N. Engl. J. Med 315, 1459–1468 (1986).
Wilson, A. C., Meethal, S. V., Bowen, R. L. & Atwood, C. S. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin. Investig. Drugs 16, 1851–1863 (2007).
Hoda, M. R., Kramer, M. W., Merseburger, A. S. & Cronauer, M. V. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer. Expert Opin. Pharmacother. 18, 105–113 (2017).
Uttley, L. et al. Degarelix for treating advanced hormone-dependent prostate cancer: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics 35, 717–726 (2017).
Lamberts, S. W. J. & Hofland, L. J. ANNIVERSARY REVIEW: octreotide, 40 years later. Eur. J. Endocrinol. 181, R173–R183 (2019).
Pokuri, V. K., Fong, M. K. & Iyer, R. Octreotide and lanreotide in gastroenteropancreatic neuroendocrine tumors. Curr. Oncol. Rep. 18, 7 (2016).
Svensson, P. J., Bergqvist, P. B., Juul, K. V. & Berntorp, E. Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. Blood Rev. 28, 95–102 (2014).
Theunissen, F. J., Chinery, L. & Pujar, Y. V. Current research on carbetocin and implications for prevention of postpartum haemorrhage. Reprod. Health 15, 94 (2018).
Kim, S. H. et al. The oxytocin receptor antagonist, Atosiban, activates pro-inflammatory pathways in human amnion via G(alphai) signalling. Mol. Cell Endocrinol. 420, 11–23 (2016).
Brown, M. C. et al. VEGF-related protein isolated from Vipera palestinae venom, promotes angiogenesis. Growth Factors 25, 108–117 (2007).
Yamazaki, Y. et al. Snake venom vascular endothelial growth factors (VEGF-Fs) exclusively vary their structures and functions among species. J. Biol. Chem. 284, 9885–9891 (2009).
Toivanen, P. I. et al. Snake venom VEGF Vammin induces a highly efficient angiogenic response in skeletal muscle via VEGFR-2/NRP specific signaling. Sci Rep-Uk. 7, 5525 (2017).
Wulff, H. et al. Antibodies and venom peptides: new modalities for ion channels. Nat. Rev. Drug Disco. 18, 339–357 (2019).
Miller, L. J., Sexton, P. M., Dong, M. & Harikumar, K. G. The class B G-protein-coupled GLP-1 receptor: an important target for the treatment of type-2 diabetes mellitus. Int J. Obes. Suppl. 4, S9–S13 (2014).
Schmidtko, A., Lotsch, J., Freynhagen, R. & Geisslinger, G. Ziconotide for treatment of severe chronic pain. Lancet 375, 1569–1577 (2010).
Pope, J. E. et al. The pharmacology of spinal opioids and ziconotide for the treatment of non-cancer pain. Curr. Neuropharmacol. 15, 206–216 (2017).
Walsh, C. T. Insights into the chemical logic and enzymatic machinery of NRPS assembly lines. Nat. Prod. Rep. 33, 127–135 (2016).
Marahiel, M. A. Working outside the protein-synthesis rules: insights into non-ribosomal peptide synthesis. J. Pept. Sci. 15, 799–807 (2009).
Awan, A. R., Shaw, W. M. & Ellis, T. Biosynthesis of therapeutic natural products using synthetic biology. Adv. Drug Deliv. Rev. 105, 96–106 (2016).
Schilling, N. A. et al. Synthetic lugdunin analogues reveal essential structural motifs for antimicrobial action and proton translocation capability. Angew. Chem. Int Ed. Engl. 58, 9234–9238 (2019).
Bitschar, K. et al. Lugdunin amplifies innate immune responses in the skin in synergy with host- and microbiota-derived factors. Nat. Commun. 10, 2730 (2019).
Niu, X., Thaochan, N. & Hu, Q. Diversity of linear non-ribosomal peptide in biocontrol fungi. J Fungi (Basel). 6, 61 (2020).
Brown, A. S., Calcott, M. J., Owen, J. G. & Ackerley, D. F. Structural, functional and evolutionary perspectives on effective re-engineering of non-ribosomal peptide synthetase assembly lines. Nat. Prod. Rep. 35, 1210–1228 (2018).
Gould, A., Ji, Y., Aboye, T. L. & Camarero, J. A. Cyclotides, a novel ultrastable polypeptide scaffold for drug discovery. Curr. Pharm. Des. 17, 4294–4307 (2011).
Sivanathan, S. & Scherkenbeck, J. Cyclodepsipeptides: a rich source of biologically active compounds for drug research. Molecules 19, 12368–12420 (2014).
Weidmann, J. & Craik, D. J. Discovery, structure, function, and applications of cyclotides: circular proteins from plants. J. Exp. Bot. 67, 4801–4812 (2016).
Prosperini, A. et al. A review of the mycotoxin enniatin B. Front Public Health 5, 304 (2017).
Martin, R. J. et al. Emodepside and SL0-1 potassium channels: a review. Exp. Parasitol. 132, 40–46 (2012).
Bonetta, L. Protein-protein interactions: Interactome under construction. Nature 468, 851–854 (2010).
Vidal, M., Cusick, M. E. & Barabasi, A. L. Interactome networks and human disease. Cell 144, 986–998 (2011).
Rolland, T. et al. A proteome-scale map of the human interactome network. Cell 159, 1212–1226 (2014).
Lee, A. C., Harris, J. L., Khanna, K. K. & Hong, J. H. A. Comprehensive review on current advances in peptide drug development and design. Int J Mol Sci. 20, 2383 (2019).
Hill, T. A., Shepherd, N. E., Diness, F. & Fairlie, D. P. Constraining cyclic peptides to mimic protein structure motifs. Angew. Chem. Int Ed. Engl. 53, 13020–13041 (2014).
Nevola, L. & Giralt, E. Modulating protein-protein interactions: the potential of peptides. Chem. Commun. (Camb.) 51, 3302–3315 (2015).
Geppert, T., Hoy, B., Wessler, S. & Schneider, G. Context-based identification of protein-protein interfaces and “hot-spot” residues. Chem. Biol. 18, 344–353 (2011).
Cukuroglu, E., Engin, H. B., Gursoy, A. & Keskin, O. Hot spots in protein-protein interfaces: towards drug discovery. Prog. Biophys. Mol. Biol. 116, 165–173 (2014).
Liu, D. G. et al. Small molecules engage hot spots through cooperative binding to inhibit a tight protein-protein interaction. Biochem.-Us 56, 1768–1784 (2017).
Villar, E. A. et al. How proteins bind macrocycles. Nat. Chem. Biol. 10, 723–731 (2014).
Wojcik, P. & Berlicki, L. Peptide-based inhibitors of protein-protein interactions. Bioorg. Med Chem. Lett. 26, 707–713 (2016).
Bhat, A., Roberts, L. R. & Dwyer, J. J. Lead discovery and optimization strategies for peptide macrocycles. Eur. J. Medicinal Chem. 94, 471–479 (2015).
Vinogradov, A. A., Yin, Y. & Suga, H. Macrocyclic peptides as drug candidates: recent progress and remaining challenges. J. Am. Chem. Soc. 141, 4167–4181 (2019).
Smith, G. P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315–1317 (1985).
Omidfar, K. & Daneshpour, M. Advances in phage display technology for drug discovery. Expert Opin. Drug Disco. 10, 651–669 (2015).
Frenzel, A., Schirrmann, T. & Hust, M. Phage display-derived human antibodies in clinical development and therapy. MAbs 8, 1177–1194 (2016).
Giustina, A. et al. EXPERT CONSENSUS DOCUMENT A consensus on the medical treatment of acromegaly. Nat. Rev. Endocrinol. 10, 243–248 (2014).
Zhang, H. K., Xie, J. & Lerner, R. A. A proximity based general method for identification of ligand and receptor interactions in living cells. Biochem Bioph Res Co. 454, 251–255 (2014).
Peng, Y. J. et al. A general method for insertion of functional proteins within proteins via combinatorial selection of permissive junctions. Chem. Biol. 22, 1134–1143 (2015).
Zhang, H. K. et al. Autocrine-based selection of drugs that target ion channels from combinatorial venom peptide libraries. Angew. Chem. Int Ed. 55, 9306–9310 (2016).
Zhang, H. K. et al. Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects. Nat Commun. 6, 8918 (2015).
Zong, X. L. et al. Phage Display, Peptide Production and Biological Assessment of Key Sequence of TGF-beta 1. Int J. Pept. Res Ther. 25, 1217–1223 (2019).
Yoshimoto, N. et al. High-throughput de novo screening of receptor agonists with an automated single-cell analysis and isolation system. Sci Rep-Uk. 4, 4242 (2014).
Lipok, M. et al. Identification of a peptide antagonist of the FGF1-FGFR1 signaling axis by phage display selection. Febs Open Bio 9, 914–924 (2019).
Matochko, W. L. & Derda, R. Next-generation sequencing of phage-displayed peptide libraries. Methods Mol. Biol. 1248, 249–266 (2015).
Heinis, C. & Winter, G. Encoded libraries of chemically modified peptides. Curr. Opin. Chem. Biol. 26, 89–98 (2015).
Schumacher, T. N. et al. Identification of D-peptide ligands through mirror-image phage display. Science 271, 1854–1857 (1996).
Diaz-Perlas, C. et al. Protein chemical synthesis combined with mirror-image phage display yields d-peptide EGF ligands that block the EGF-EGFR interaction. Chembiochem 20, 2079–2084 (2019).
Josephson, K., Ricardo, A. & Szostak, J. W. mRNA display: from basic principles to macrocycle drug discovery. Drug Disco. Today 19, 388–399 (2014).
Baggio, R. et al. Identification of epitope-like consensus motifs using mRNA display. J. Mol. Recognit. 15, 126–134 (2002).
Schlippe, Y. V. G., Hartman, M. C. T., Josephson, K. & Szostak, J. W. In vitro selection of highly modified cyclic peptides that act as tight binding inhibitors. J. Am. Chem. Soc. 134, 10469–10477 (2012).
Morioka, T. et al. Selection-based discovery of macrocyclic peptides for the next generation therapeutics. Curr. Opin. Chem. Biol. 26, 34–41 (2015).
Ohuchi, M., Murakami, H. & Suga, H. The flexizyme system: a highly flexible tRNA aminoacylation tool for the translation apparatus. Curr. Opin. Chem. Biol. 11, 537–542 (2007).
Passioura, T., Katoh, T., Goto, Y. & Suga, H. Selection-based discovery of druglike macrocyclic peptides. Annu Rev. Biochem. 83, 727–752 (2014).
Merrifield, R. B. Solid phase peptide synthesis. i. the synthesis of a tetrapeptide. J. Am. Chem. Soc. 85, 2149–2154 (1963).
Hackenberger, C. P. R., Dawson, P. E., Chen, Y. X. & Hojo, H. Modern peptide and protein chemistry: reaching new heights. J. Org. Chem. 85, 1328–1330 (2020).
Jaradat, D. M. M. Thirteen decades of peptide synthesis: key developments in solid phase peptide synthesis and amide bond formation utilized in peptide ligation. Amino Acids 50, 39–68 (2018).
Puentes, A. R., Morejon, M. C., Rivera, D. G. & Wessjohann, L. A. Peptide macrocyclization assisted by traceless turn inducers derived from Ugi peptide ligation with cleavable and resin-linked amines. Org. Lett. 19, 4022–4025 (2017).
Behrendt, R., White, P. & Offer, J. Advances in Fmoc solid-phase peptide synthesis. J. Pept. Sci. 22, 4–27 (2016).
Weidmann, J., Dimitrijevic, E., Hoheisel, J. D. & Dawson, P. E. Boc-SPPS: compatible linker for the synthesis of peptide o-aminoanilides. Org. Lett. 18, 164–167 (2016).
Wolczanski, G. & Lisowski, M. A general method for preparation of N-Boc-protected or N-Fmoc-protected alpha,beta-didehydropeptide building blocks and their use in the solid-phase peptide synthesis. J. Pept. Sci. 24, e3091 (2018).
Coin, I., Beyermann, M. & Bienert, M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nat. Protoc. 2, 3247–3256 (2007).
Garcia-Martin, F. et al. ChemMatrix, a poly(ethylene glycol)-based support for the solid-phase synthesis of complex peptides. J. Comb. Chem. 8, 213–220 (2006).
Pedersen, S. L., Tofteng, A. P., Malik, L. & Jensen, K. J. Microwave heating in solid-phase peptide synthesis. Chem. Soc. Rev. 41, 1826–1844 (2012).
Paradis-Bas, M., Tulla-Puche, J. & Albericio, F. The road to the synthesis of “difficult peptides”. Chem. Soc. Rev. 45, 631–654 (2016).
Palasek, S. A., Cox, Z. J. & Collins, J. M. Limiting racemization and aspartimide formation in microwave-enhanced Fmoc solid phase peptide synthesis. J. Pept. Sci. 13, 143–148 (2007).
Cardona, V. et al. Application of Dmb-dipeptides in the Fmoc SPPS of difficult and aspartimide-prone sequences. Int J. Pept. Res Ther. 14, 285–292 (2008).
Michels, T., Dolling, R., Haberkorn, U. & Mier, W. Acid-mediated prevention of aspartimide formation in solid phase peptide synthesis. Org. Lett. 14, 5218–5221 (2012).
Subiros-Funosas, R., El-Faham, A. & Albericio, F. Use of Oxyma as pH modulatory agent to be used in the prevention of base-driven side reactions and its effect on 2-chlorotrityl chloride resin. Biopolymers 98, 89–97 (2012).
Gentilucci, L., Tolomelli, A. & Squassabia, F. Peptides and peptidomimetics in medicine, surgery and biotechnology. Curr. Med Chem. 13, 2449–2466 (2006).
Varela, Y. F., Vanegas Murcia, M. & Patarroyo, M. E. Synthetic evaluation of standard and microwave-assisted solid phase peptide synthesis of a long chimeric peptide derived from four plasmodium falciparum proteins. Molecules. 23, 2877 (2018).
Hansen, A. M. et al. Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae. Eur. J. Med Chem. 168, 134–145 (2019).
Di, L. Strategic approaches to optimizing peptide ADME properties. AAPS J. 17, 134–143 (2015).
Jamieson, A. G., Boutard, N., Sabatino, D. & Lubell, W. D. Peptide scanning for studying structure-activity relationships in drug discovery. Chem. Biol. Drug Des. 81, 148–165 (2013).
Eustache, S., Leprince, J. & Tuffery, P. Progress with peptide scanning to study structure-activity relationships: the implications for drug discovery. Expert Opin. Drug Disco. 11, 771–784 (2016).
Goodwin, D., Simerska, P. & Toth, I. Peptides as therapeutics with enhanced bioactivity. Curr. Medicinal Chem. 19, 4451–4461 (2012).
Miranda, L. P. et al. Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J. Med Chem. 51, 7889–7897 (2008).
Werner, H. M., Cabalteja, C. C. & Horne, W. S. Peptide backbone composition and protease susceptibility: impact of modification type, position, and tandem substitution. Chembiochem 17, 712–718 (2016).
Wei, X. et al. Retro-inverso isomer of Angiopep-2: a stable d-peptide ligand inspires brain-targeted drug delivery. Mol. Pharm. 11, 3261–3268 (2014).
Chatterjee, J., Rechenmacher, F. & Kessler, H. N-methylation of peptides and proteins: an important element for modulating biological functions. Angew. Chem. Int Ed. Engl. 52, 254–269 (2013).
Cheloha, R. W. et al. Backbone modification of a parathyroid hormone receptor-1 antagonist/inverse agonist. ACS Chem. Biol. 11, 2752–2762 (2016).
Liskamp, R. M. J., Rijkers, D. T. S., Kruijtzer, J. A. W. & Kemmink, J. Peptides and proteins as a continuing exciting source of inspiration for peptidomimetics. Chembiochem 12, 1626–1653 (2011).
Schneider, J. A. et al. Design of peptoid-peptide macrocycles to Inhibit the beta-catenin TCF interaction in prostate cancer. Nat Commun. 9, 4396 (2018).
Olsen, C. A., Montero, A., Leman, L. J. & Ghadiri, M. R. Macrocyclic peptoid-peptide hybrids as inhibitors of class I histone deacetylases. Acs Med Chem. Lett. 3, 749–753 (2012).
Wisniewski, K. et al. New, potent, selective, and short-acting peptidic V1a receptor agonists. J. Med Chem. 54, 4388–4398 (2011).
Maybauer, M. O. et al. The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*. Crit. Care Med 42, e525–e533 (2014).
Masri, E., Ahsanullah, Accorsi, M. & Rademann, J. Side-chain modification of peptides using a phosphoranylidene amino acid. Org. Lett. 22, 2976–2980 (2020).
Frey, V. et al. Structure-activity relationships of Bak derived peptides: affinity and specificity modulations by amino acid replacement. Eur. J. Medicinal Chem. 43, 966–972 (2008).
Hone, A. J. et al. PeIA-5466: a novel peptide antagonist containing non-natural amino acids that selectively targets alpha 3 beta 2 nicotinic acetylcholine receptors. J. Medicinal Chem. 62, 6262–6275 (2019).
Milroy, L. G. et al. Modulators of protein-protein interactions. Chem. Rev. 114, 4695–4748 (2014).
Pelay-Gimeno, M., Glas, A., Koch, O. & Grossmann, T. N. Structure-based design of inhibitors of protein-protein interactions: mimicking peptide binding epitopes. Angew. Chem. Int Ed. Engl. 54, 8896–8927 (2015).
White, C. J. & Yudin, A. K. Contemporary strategies for peptide macrocyclization. Nat. Chem. 3, 509–524 (2011).
Pelay-Gimeno, M., Tulla-Puche, J. & Albericio, F. “Head-to-side-chain” cyclodepsipeptides of marine origin. Mar. Drugs 11, 1693–1717 (2013).
Mourao, C. B. F. et al. Head-to-tail cyclization after interaction with trypsin: a scorpion venom peptide that resembles plant cyclotides. J. Medicinal Chem. 63, 9500–9511 (2020).
Yang, P. Y. et al. Stapled, long-acting glucagon-like peptide 2 analog with efficacy in dextran sodium sulfate induced mouse colitis models. J. Med Chem. 61, 3218–3223 (2018).
Ricardo, M. G. et al. Multicomponent peptide stapling as a diversity-driven tool for the development of inhibitors of protein-protein interactions. Angew. Chem. Int Ed. 59, 5235–5241 (2020).
Dougherty, P. G. et al. Enhancing the cell permeability of stapled peptides with a cyclic cell-penetrating peptide. J. Medicinal Chem. 62, 10098–10107 (2019).
Perry, S. R. et al. Contiguous hydrophobic and charged surface patches in short helix-constrained peptides drive cell permeability. Org. Biomol. Chem. 16, 367–371 (2018).
Tian, Y. et al. Effect of stapling architecture on physiochemical properties and cell permeability of stapled alpha-helical peptides: a comparative study. Chembiochem 18, 2087–2093 (2017).
Li, C. Y. et al. Binding loop substitutions in the cyclic peptide SFTI-1 generate potent and selective chymase inhibitors. J. Medicinal Chem. 63, 816–826 (2020).
Miao, J. Y. et al. Designing cyclic-peptide inhibitors of protein-protein interactions by mimicking hot loops. Abstr Pap Am Chem S. 256, 434 (2018).
Neukirchen, S. et al. Cyclic peptides for targeting helical protein-protein interactions. J. Pept. Sci. 22, S50–S52 (2016).
Ricardo, M. G., Vasco, A. V., Rivera, D. G. & Wessjohann, L. A. Stabilization of Cyclic beta-Hairpins by Ugi-Reaction-Derived N-Alkylated Peptides: The Quest for Functionalized beta-Turns. Org. Lett. 21, 7307–7310 (2019).
van der Knaap, M. et al. Design, synthesis and structural analysis of mixed alpha/beta-peptides that adopt stable cyclic hairpin-like conformations. Tetrahedron 68, 2391–2400 (2012).
Koch, O., Cole, J., Block, P. & Klebe, G. Secbase: database module to retrieve secondary structure elements with ligand binding motifs. J. Chem. Inf. Model 49, 2388–2402 (2009).
Bullock, B. N., Jochim, A. L. & Arora, P. S. Assessing helical protein interfaces for inhibitor design. J. Am. Chem. Soc. 133, 14220–14223 (2011).
Jochim, A. L. & Arora, P. S. Systematic analysis of helical protein interfaces reveals targets for synthetic inhibitors. ACS Chem. Biol. 5, 919–923 (2010).
Bergey, C. M., Watkins, A. M. & Arora, P. S. HippDB: a database of readily targeted helical protein-protein interactions. Bioinformatics 29, 2806–2807 (2013).
Sawyer, N., Watkins, A. M. & Arora, P. S. Protein domain mimics as modulators of protein-protein interactions. Acc. Chem. Res 50, 1313–1322 (2017).
Khoo, K. K. et al. Lactam-stabilized helical analogues of the analgesic mu-conotoxin KIIIA. J. Med Chem. 54, 7558–7566 (2011).
Galande, A. K. et al. Thioether side chain cyclization for helical peptide formation: inhibitors of estrogen receptor-coactivator interactions. J. Pept. Res 63, 297–302 (2004).
Muppidi, A. et al. Rational design of proteolytically stable, cell-permeable peptide-based selective Mcl-1 inhibitors. J. Am. Chem. Soc. 134, 14734–14737 (2012).
Muppidi, A. et al. Design of antiviral stapled peptides containing a biphenyl cross-linker. Bioorg. Med Chem. Lett. 24, 1748–1751 (2014).
Sakagami, K., Masuda, T., Kawano, K. & Futaki, S. Importance of net hydrophobicity in the cellular uptake of all-hydrocarbon stapled peptides. Mol. Pharm. 15, 1332–1340 (2018).
Reguera, L. & Rivera, D. G. Multicomponent reaction toolbox for peptide macrocyclization and stapling. Chem. Rev. 119, 9836–9860 (2019).
Cabezas, E. & Satterthwait, A. C. The hydrogen bond mimic approach: Solid-phase synthesis of a peptide stabilized as an alpha-helix with a hydrazone link. J. Am. Chem. Soc. 121, 3862–3875 (1999).
Chapman, R. N., Dimartino, G. & Arora, P. S. A highly stable short alpha-helix constrained by a main-chain hydrogen-bond surrogate. J. Am. Chem. Soc. 126, 12252–12253 (2004).
Patgiri, A., Menzenski, M. Z., Mahon, A. B. & Arora, P. S. Solid-phase synthesis of short alpha-helices stabilized by the hydrogen bond surrogate approach. Nat. Protoc. 5, 1857–1865 (2010).
Patgiri, A., Witten, M. R. & Arora, P. S. Solid phase synthesis of hydrogen bond surrogate derived alpha-helices: resolving the case of a difficult amide coupling. Org. Biomol. Chem. 8, 1773–1776 (2010).
Chapman, R. N. & Arora, P. S. Optimized synthesis of hydrogen-bond surrogate helices: surprising effects of microwave heating on the activity of grubbs catalysts. Org. Lett. 8, 5825–5828 (2006).
Sawyer, N. & Arora, P. S. Hydrogen bond surrogate stabilization of beta-hairpins. Acs Chem. Biol. 13, 2027–2032 (2018).
Sawyer, N. & Arora, P. S. Hydrogen bond surrogate beta-hairpins to inhibit protein-protein interactions. Biophys. J. 114, 56a–57a (2018).
Sawyer, N. & Arora, P. S. Using hydrogen bond surrogate technology to stabilize beta-hairpins. Biophys. J. 112, 177a–177a (2017).
Kushal, S. et al. Hydrogen bond surrogate (HBS) helices as orthosteric regulator of hypoxia inducible transcription. Cancer Res. 72, 289 (2012).
Henchey, L. K., Porter, J. R., Ghosh, I. & Arora, P. S. High specificity in protein recognition by hydrogen-bond-surrogate alpha-helices: selective inhibition of the p53/MDM2 complex. Chembiochem 11, 2104–2107 (2010).
Bao, J., Dong, X. Y., Zhang, J. Z. H. & Arora, P. S. Dynamical binding of hydrogen-bond surrogate derived bak helices to antiapoptotic protein Bcl-x(L). J. Phys. Chem. B 113, 3565–3571 (2009).
Wang, L. et al. Synthesis and characterization of water-soluble macrocyclic peptides stabilizing protein alpha-turn. Org. Biomol. Chem. 16, 459–471 (2018).
Wang, L. et al. Solid phase synthesis of constrained 13-membered peptide macrocycles employing Fukuyama-Mitsunobu alkylations. Tetrahedron Lett. 56, 2456–2459 (2015).
Athanassiou, Z. et al. Structural mimicry of retroviral tat proteins by constrained beta-hairpin peptidomimetics: ligands with high affinity and selectivity for viral TAR RNA regulatory elements. J. Am. Chem. Soc. 126, 6906–6913 (2004).
Fasan, R. et al. Using a beta-hairpin to mimic an alpha-helix: Cyclic peptidomimetic inhibitors of the p53-HDM2 protein-protein interaction. Angew. Chem. Int Ed. 43, 2109–2112 (2004).
Cheng, P. N. et al. Amyloid beta-sheet mimics that antagonize protein aggregation and reduce amyloid toxicity. Nat. Chem. 4, 927–933 (2012).
Liu, C. et al. Characteristics of amyloid-related oligomers revealed by crystal structures of macrocyclic beta-sheet mimics. J. Am. Chem. Soc. 133, 6736–6744 (2011).
Konig, H. M. & Kilbinger, A. F. M. Learning from nature: beta-sheet-mimicking copolymers get organized. Angew. Chem. Int Ed. 46, 8334–8340 (2007).
Khakshoor, O., Demeler, B. & Nowick, J. S. Macrocyclic beta-sheet peptides that mimic protein quaternary structure through intermolecular beta-sheet interactions. J. Am. Chem. Soc. 129, 5558–5569 (2007).
Taylor, M. et al. Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer’s disease. Biochem.-Us 49, 3261–3272 (2010).
Tian, Y. A. et al. Solid-phase extraction of N-linked glycopeptides. Nat. Protoc. 2, 334–339 (2007).
Kumar, D. & Bhalla, T. C. Microbial proteases in peptide synthesis: approaches and applications. Appl Microbiol Biot. 68, 726–736 (2005).
Sanjukta, S. & Rai, A. K. Production of bioactive peptides during soybean fermentation and their potential health benefits. Trends Food Sci. Tech. 50, 1–10 (2016).
Sultan, S. et al. Therapeutic potential of dairy bioactive peptides: a contemporary perspective. Crit. Rev. Food Sci. 58, 105–115 (2018).
Vlieghe, P., Lisowski, V., Martinez, J. & Khrestchatisky, M. Synthetic therapeutic peptides: science and market. Drug Discov. Today 15, 40–56 (2010).
Bristow, A. F. Recombinant-DNA-derived insulin analogs as potentially useful therapeutic agents. Trends Biotechnol. 11, 301–305 (1993).
Conibear, A. C., Watson, E. E., Payne, R. J. & Becker, C. F. W. Native chemical ligation in protein synthesis and semi-synthesis. Chem. Soc. Rev. 47, 9046–9068 (2018).
Hirasawa, S. et al. Facile and efficient chemoenzymatic semisynthesis of Fc-fusion compounds for half-life extension of pharmaceutical components. Bioconjugate Chem. 30, 2323–2331 (2019).
Sampaio de Oliveira, K. B. et al. Strategies for recombinant production of antimicrobial peptides with pharmacological potential. Expert Rev. Clin. Pharmacol. 13, 367–390 (2020).
Wibowo, D. & Zhao, C. X. Recent achievements and perspectives for large-scale recombinant production of antimicrobial peptides. Appl Microbiol Biotechnol. 103, 659–671 (2019).
Banting, F. G. et al. Pancreatic extracts in the treatment of diabetes mellitus. Can. Med Assoc. J. 12, 141–146 (1922).
Quianzon, C. C. & Cheikh, I. History of insulin. J Community Hosp Intern Med Perspect. 2, 2 (2012).
Elkinton, J. R. & Hunt, A. D. Jr Effects of pituitary adrenocorticotropic hormone therapy. J. Am. Med Assoc. 141, 1273–1279 (1949).
Copp, D. H. Calcitonin: discovery, development, and clinical application. Clin. Invest Med 17, 268–277 (1994).
Lewis, R. J. & Garcia, M. L. Therapeutic potential of venom peptides. Nat. Rev. Drug Disco. 2, 790–802 (2003).
King, G. F. Venoms as a platform for human drugs: translating toxins into therapeutics. Expert Opin. Biol. Th 11, 1469–1484 (2011).
de Veer, S. J., Kan, M. W. & Craik, D. J. Cyclotides: from structure to function. Chem. Rev. 119, 12375–12421 (2019).
Ojeda, P. G., Cardoso, M. H. & Franco, O. L. Pharmaceutical applications of cyclotides. Drug Disco. Today 24, 2152–2161 (2019).
Kim, D. R. et al. Function and distribution of a lantipeptide in strawberry fusarium wilt disease-suppressive soils. Mol. Plant Microbe Interact. 32, 306–312 (2019).
Murthy, M. V. R., Mohan, E. V. S. & Sadhukhan, A. K. Cyclosporin-A production by Tolypocladium inflatum using solid state fermentation. Process Biochem 34, 269–280 (1999).
Dik, D. A. et al. Semisynthesis of a bacterium with non-canonical cell-wall cross-links. J. Am. Chem. Soc. 142, 10910–10913 (2020).
Franck, C. et al. Semisynthesis of an evasin from tick saliva reveals a critical role of tyrosine sulfation for chemokine binding and inhibition. Proc. Natl Acad. Sci. USA 117, 12657–12664 (2020).
Deng, Y. et al. Semisynthesis of platensimycin derivatives with antibiotic activities in mice via Suzuki-Miyaura cross-coupling reactions. J. Med Chem. 61, 11341–11348 (2018).
Wang, L., Brock, A., Herberich, B. & Schultz, P. G. Expanding the genetic code of Escherichia coli. Science 292, 498–500 (2001).
Wang, L. & Schultz, P. G. Expanding the genetic code. Angew. Chem. Int Ed. Engl. 44, 34–66 (2004).
Oller-Salvia, B. & Chin, J. W. Efficient phage display with multiple distinct non-canonical amino acids using orthogonal ribosome-mediated genetic code expansion. Angew. Chem. Int Ed. Engl. 58, 10844–10848 (2019).
Wang, L. Engineering the genetic code in cells and animals: biological considerations and impacts. Acc. Chem. Res 50, 2767–2775 (2017).
Santoro, S. W. et al. An efficient system for the evolution of aminoacyl-tRNA synthetase specificity. Nat. Biotechnol. 20, 1044–1048 (2002).
Anderson, J. C. et al. An expanded genetic code with a functional quadruplet codon. Proc. Natl Acad. Sci. USA 101, 7566–7571 (2004).
Niu, W., Schultz, P. G. & Guo, J. An expanded genetic code in mammalian cells with a functional quadruplet codon. ACS Chem. Biol. 8, 1640–1645 (2013).
Valentini, T. D. et al. Bioorthogonal non-canonical amino acid tagging reveals translationally active subpopulations of the cystic fibrosis lung microbiota. Nat. Commun. 11, 2287 (2020).
Ernst, R. J. et al. Genetic code expansion in the mouse brain. Nat. Chem. Biol. 12, 776–778 (2016).
Liu, J. et al. Genetic code expansion in zebrafish embryos and its application to optical control of cell signaling. J. Am. Chem. Soc. 139, 9100–9103 (2017).
Brown, W., Liu, J. & Deiters, A. Genetic code expansion in animals. ACS Chem. Biol. 13, 2375–2386 (2018).
Chin, J. W. et al. An expanded eukaryotic genetic code. Science 301, 964–967 (2003).
Wang, N. X. et al. Construction of a live-attenuated HIV-1 vaccine through genetic code expansion. Angew. Chem. Int Ed. 53, 4867–4871 (2014).
Si, L. et al. Generation of influenza A viruses as live but replication-incompetent virus vaccines. Science 354, 1170–1173 (2016).
Zheng, Y. et al. Broadening the versatility of lentiviral vectors as a tool in nucleic acid research via genetic code expansion. Nucleic Acids Res 43, e73 (2015).
Lang, K. & Chin, J. W. Bioorthogonal reactions for labeling proteins. ACS Chem. Biol. 9, 16–20 (2014).
Hu, C. et al. Metalloprotein design using genetic code expansion. Chem. Soc. Rev. 43, 6498–6510 (2014).
Nguyen, T. A., Cigler, M. & Lang, K. Expanding the genetic code to study protein-protein interactions. Angew. Chem. Int Ed. Engl. 57, 14350–14361 (2018).
Courtney, T. & Deiters, A. Recent advances in the optical control of protein function through genetic code expansion. Curr. Opin. Chem. Biol. 46, 99–107 (2018).
Zhou, W. & Deiters, A. Chemogenetic and optogenetic control of post-translational modifications through genetic code expansion. Curr. Opin. Chem. Biol. 63, 123–131 (2021).
Debelouchina, G. T. & Muir, T. W. A molecular engineering toolbox for the structural biologist. Q Rev. Biophys. 50, e7 (2017).
Hoppmann, C. et al. Site-specific incorporation of phosphotyrosine using an expanded genetic code. Nat. Chem. Biol. 13, 842–844 (2017).
He, X. et al. Functional genetic encoding of sulfotyrosine in mammalian cells. Nat. Commun. 11, 4820 (2020).
Italia, J. S. et al. Genetically encoded protein sulfation in mammalian cells. Nat. Chem. Biol. 16, 379–382 (2020).
Neumann, H., Peak-Chew, S. Y. & Chin, J. W. Genetically encoding N(epsilon)-acetyllysine in recombinant proteins. Nat. Chem. Biol. 4, 232–234 (2008).
Krauskopf, K. & Lang, K. Increasing the chemical space of proteins in living cells via genetic code expansion. Curr. Opin. Chem. Biol. 58, 112–120 (2020).
Drienovska, I. & Roelfes, G. Expanding the enzyme universe with genetically encoded unnatural amino acids. Nat. Catal. 3, 193–202 (2020).
Jevsevar, S., Kunstelj, M. & Porekar, V. G. PEGylation of therapeutic proteins. Biotechnol. J. 5, 113–128 (2010).
Veronese, F. M. & Mero, A. The impact of PEGylation on biological therapies. BioDrugs 22, 315–329 (2008).
Gupta, V. et al. Protein PEGylation for cancer therapy: bench to bedside. J. Cell Commun. Signal 13, 319–330 (2019).
Zhang, C. et al. Site-specific PEGylation of therapeutic proteins via optimization of both accessible reactive amino acid residues and PEG derivatives. Biodrugs 26, 209–215 (2012).
Deiters, A. et al. Site-specific PEGylation of proteins containing unnatural amino acids. Bioorg. Med Chem. Lett. 14, 5743–5745 (2004).
Zhang, B. et al. Development of next generation of therapeutic IFN-alpha2b via genetic code expansion. Acta Biomater. 19, 100–111 (2015).
Cho, H. et al. Optimized clinical performance of growth hormone with an expanded genetic code. Proc. Natl Acad. Sci. USA 108, 9060–9065 (2011).
Wu, L. et al. Precise and combinatorial PEGylation generates a low-immunogenic and stable form of human growth hormone. J. Control Release 249, 84–93 (2017).
Shozen, N., Iijima, I. & Hohsaka, T. Site-specific incorporation of PEGylated amino acids into proteins using nonnatural amino acid mutagenesis. Bioorg. Med Chem. Lett. 19, 4909–4911 (2009).
Tada, S. et al. Genetic PEGylation. PLoS One 7, e49235 (2012).
Fu, C. et al. Genetically encoding a lipidated amino acid for extension of protein half-life. vivo. Angew. Chem. Int Ed. Engl. 58, 1392–1396 (2019).
Fok, J. A. & Mayer, C. Genetic-code-expansion strategies for vaccine development. Chembiochem 21, 3291–3300 (2020).
Huang, Y. & Liu, T. Therapeutic applications of genetic code expansion. Synth. Syst. Biotechnol. 3, 150–158 (2018).
Grunewald, J. et al. Immunochemical termination of self-tolerance. Proc. Natl Acad. Sci. USA 105, 11276–11280 (2008).
Gauba, V. et al. Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids. Proc. Natl Acad. Sci. USA 108, 12821–12826 (2011).
Wang, F. et al. Genetic incorporation of unnatural amino acids into proteins in mycobacterium tuberculosis. Plos One. 5, e9354 (2010).
Lin, S. X. et al. Site-specific engineering of chemical functionalities on the surface of live hepatitis D virus. Angew. Chem. Int Ed. 52, 13970–13974 (2013).
Yuan, Z. et al. Controlling multicycle replication of live-attenuated HIV-1 using an unnatural genetic switch. ACS Synth. Biol. 6, 721–731 (2017).
Chen, Y. et al. Controlling the replication of a genomically recoded HIV-1 with a functional quadruplet codon in mammalian cells. ACS Synth. Biol. 7, 1612–1617 (2018).
Lonsdale, R. & Ward, R. A. Structure-based design of targeted covalent inhibitors. Chem. Soc. Rev. 47, 3816–3830 (2018).
Singh, J., Petter, R. C., Baillie, T. A. & Whitty, A. The resurgence of covalent drugs. Nat. Rev. Drug Disco. 10, 307–317 (2011).
Sutanto, F., Konstantinidou, M. & Domling, A. Covalent inhibitors: a rational approach to drug discovery. RSC Med Chem. 11, 876–884 (2020).
Li, Q. K. et al. Developing covalent protein drugs via proximity-enabled reactive therapeutics. Cell 182, 85 (2020). -+.
Wang, N. et al. Genetically encoding fluorosulfate-l-tyrosine to react with lysine, histidine, and tyrosine via SuFEx in proteins in Vivo. J. Am. Chem. Soc. 140, 4995–4999 (2018).
Berdan, V. Y., Klauser, P. C. & Wang, L. Covalent peptides and proteins for therapeutics. Bioorg. Med Chem. 29, 115896 (2021).
Pollaro, L. & Heinis, C. Strategies to prolong the plasma residence time of peptide drugs. Medchemcomm 1, 319–324 (2010).
Kaji, I., Karaki, S. & Kuwahara, A. Short-chain fatty acid receptor and its contribution to glucagon-like peptide-1 release. Digestion 89, 31–36 (2014).
Stewart, M. W. et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide (Syncria (R)), a long-acting GLP-1 mimetic, in subjects with type 2 diabetes. Diabetes 57, A154–A154 (2008).
Fala, L. Trulicity (Dulaglutide): a new GLP-1 receptor agonist once-weekly subcutaneous injection approved for the treatment of patients with type 2 diabetes. Am. Health Drug Benefits 8, 131–134 (2015).
Fala, L. Tanzeum (Albiglutide): a once-weekly GLP-1 receptor agonist subcutaneous injection approved for the treatment of patients with type 2 diabetes. Am. Health Drug Benefits 8, 126–130 (2015).
Mitragotri, S., Burke, P. A. & Langer, R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Disco. 13, 655–672 (2014).
Cosmi, F., Laini, R. & Nicolucci, A. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med 376, 890 (2017).
Knudsen, L. B. & Lau, J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. (Lausanne) 10, 155 (2019).
Buckley, S. T. et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 10, eaar7047 (2018).
Bucheit, J. D. et al. Oral semaglutide: a review of the first oral glucagon-like peptide 1 receptor agonist. Diabetes Technol. Ther. 22, 10–18 (2020).
Biermasz, N. R. New medical therapies on the horizon: oral octreotide. Pituitary 20, 149–153 (2017).
Eldor, R., Arbit, E., Corcos, A. & Kidron, M. Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study. PLoS One 8, e59524 (2013).
Farra, R. et al. First-in-human testing of a wirelessly controlled drug delivery microchip. Sci. Transl. Med 4, 122ra121 (2012).
Kim, E. S. & Plosker, G. L. AFREZZA (R) (insulin human) inhalation powder: a review in diabetes mellitus. Drugs 75, 1679–1686 (2015).
Trujillo, J. M. & Nuffer, W. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy 34, 1174–1186 (2014).
George, C., Byun, A. & Howard-Thompson, A. New injectable agents for the treatment of type 2 diabetes part 2-glucagon-like peptide-1 (GLP-1) agonists. Am. J. Med 131, 1304–1306 (2018).
Rodbard, H. W. The clinical impact of GLP-1 receptor agonists in type 2 diabetes: focus on the long-acting analogs. Diabetes Technol. Ther. 20, S233–S241 (2018).
Tonneijck, L. et al. Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus. Am. J. Physiol. Ren. Physiol. 316, F231–F240 (2019).
von Scholten, B. J. et al. Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. J. Diabetes Complications 29, 670–674 (2015).
Greco, E. V. et al. GLP-1 Receptor Agonists and Kidney Protection. Medicina (Kaunas). 55, 233 (2019).
Thomas, M. C. The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. Diabetes Metab. 43, 2S20–22S27 (2017). Suppl 1.
Bethel, M. A. et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 6, 105–113 (2018).
Thondam, S. K. et al. A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus. Clin. Endocrinol. (Oxf.) 77, 635–637 (2012).
Cuthbertson, D. J. et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One 7, e50117 (2012).
Morano, S. et al. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study. Acta Diabetol. 52, 727–732 (2015).
Mabilleau, G., Pereira, M. & Chenu, C. Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists. J. Endocrinol. 236, R29–R42 (2018).
Li, J. et al. Glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide alters bone marrow exosome-mediated miRNA signal pathways in ovariectomized rats with type 2 diabetes. Med Sci. Monit. 23, 5410–5419 (2017).
Ahren, B. Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a rational drug development. J. Diabetes Investig. 10, 196–201 (2019).
Joseph, P. et al. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circ. Res 121, 677–694 (2017).
Goodfriend, T. L. & Calhoun, D. A. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 43, 518–524 (2004).
Simoes, E. S. A. C. & Teixeira, M. M. ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis. Pharm. Res 107, 154–162 (2016).
Correa, T. D., Takala, J. & Jakob, S. M. Angiotensin II in septic shock. Crit. Care 19, 98 (2015).
Montone, C. M. et al. Peptidomic strategy for purification and identification of potential ACE-inhibitory and antioxidant peptides in Tetradesmus obliquus microalgae. Anal. Bioanal. Chem. 410, 3573–3586 (2018).
Liao, W., Fan, H., Davidge, S. T. & Wu, J. Egg white-derived antihypertensive peptide IRW (Ile-Arg-Trp) reduces blood pressure in spontaneously hypertensive rats via the ACE2/Ang (1-7)/Mas receptor axis. Mol. Nutr. Food Res 63, e1900063 (2019).
Kuwahara, K. The natriuretic peptide system in heart failure: diagnostic and therapeutic implications. Pharm. Ther. 227, 107863 (2021).
Burnett, J. C. Jr. Atrial natriuretic peptide, heart failure and the heart as an endocrine organ. Clin. Chem. 65, 1602–1603 (2019).
Shah, S. J. & Teerlink, J. R. Nesiritide: a reappraisal of efficacy and safety. Expert Opin. Pharmacother. 8, 361–369 (2007).
Sackner-Bernstein, J. D., Kowalski, M., Fox, M. & Aaronson, K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293, 1900–1905 (2005).
Forte, M. et al. Cardiovascular Pleiotropic Effects of Natriuretic Peptides. Int J Mol Sci. 20, 3874 (2019).
Ichiki, T., Dzhoyashvili, N. & Burnett, J. C. Jr. Natriuretic peptide based therapeutics for heart failure: Cenderitide: a novel first-in-class designer natriuretic peptide. Int J. Cardiol. 281, 166–171 (2019).
Lee, C. Y. et al. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J. Clin. Pharm. 49, 668–673 (2009).
Duggan, K. A., Hodge, G., Chen, J. & Hunter, T. Vasoactive intestinal peptide infusion reverses existing myocardial fibrosis in the rat. Eur. J. Pharmacol. 862, 172629 (2019).
Dong, Y. et al. Cyclic peptide RD808 reduces myocardial injury induced by beta1-adrenoreceptor autoantibodies. Heart Vessels 34, 1040–1051 (2019).
Gao, H. R. & Gao, H. Y. Cardiovascular functions of central corticotropin-releasing factor related peptides system. Neuropeptides 75, 18–24 (2019).
Barchetta, I. et al. Greater circulating DPP4 activity is associated with impaired flow-mediated dilatation in adults with type 2 diabetes mellitus. Nutr. Metab. Cardiovasc Dis. 29, 1087–1094 (2019).
Bevins, C. L. & Salzman, N. H. Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. Nat. Rev. Microbiol 9, 356–368 (2011).
Aroniadis, O. C. & Brandt, L. J. Fecal microbiota transplantation: past, present and future. Curr. Opin. Gastroenterol. 29, 79–84 (2013).
Hold, G. L. et al. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J. Gastroenterol. 20, 1192–1210 (2014).
Baumgart, D. C. & Carding, S. R. Inflammatory bowel disease: cause and immunobiology. Lancet 369, 1627–1640 (2007).
Nemoto, H. et al. Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis. Dig. Dis. Sci. 57, 2955–2964 (2012).
Frank, D. N. et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl Acad. Sci. USA 104, 13780–13785 (2007).
Mukhopadhya, I. et al. Detection of Campylobacter concisus and other Campylobacter species in colonic biopsies from adults with ulcerative colitis. PLoS One 6, e21490 (2011).
Holani, R. et al. Proline-arginine rich (PR-39) cathelicidin: structure, expression and functional implication in intestinal health. Comp. Immunol. Microbiol Infect. Dis. 49, 95–101 (2016).
Limketkai, B. N., Parian, A. M., Shah, N. D. & Colombel, J. F. Short bowel syndrome and intestinal failure in Crohn’s disease. Inflamm. Bowel Dis. 22, 1209–1218 (2016).
Billiauws, L., Corcos, O. & Joly, F. What’s new in short bowel syndrome? Curr. Opin. Clin. Nutr. Metab. Care 21, 313–318 (2018).
Venneti, K. C. & Hewage, C. M. Conformational and molecular interaction studies of glucagon-like peptide-2 with its N-terminal extracellular receptor domain. FEBS Lett. 585, 346–352 (2011).
Lee, J. et al. Enteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport. Mol. Metab. 6, 245–255 (2017).
Nardini, P. et al. GLP-2 Prevents neuronal and glial changes in the distal colon of mice chronically treated with cisplatin. Int J Mol Sci. 21, 8875 (2020).
Pakarinen, M. P. GLP-2 cures the gut - What about the liver? EBioMedicine 46, 11–12 (2019).
Wang, W. W., Qiao, S. Y. & Li, D. F. Amino acids and gut function. Amino Acids 37, 105–110 (2009).
Marier, J. F. et al. Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn’s disease. J. Clin. Pharm. 50, 36–49 (2010).
Jeppesen, P. B. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome. JPEN J. Parenter. Enter. Nutr. 38, 45S–52S (2014).
Thymann, T. et al. Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome. J. Pediatr. Gastroenterol. Nutr. 58, 694–702 (2014).
Wisniewski, K. et al. Synthesis and pharmacological characterization of novel glucagon-like peptide-2 (GLP-2) analogues with low systemic clearance. J. Med Chem. 59, 3129–3139 (2016).
Kunkel, D. et al. Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome. Neurogastroenterol. Motil. 23, 739–e328 (2011).
Madsen, K. B. et al. Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study. Regul. Pept. 184, 30–39 (2013).
Raffort, J. et al. Insights on glicentin, a promising peptide of the proglucagon family. Biochem Med (Zagreb) 27, 308–324 (2017).
Lim, D. W. et al. Synergy of glucagon-like peptide-2 and epidermal growth factor coadministration on intestinal adaptation in neonatal piglets with short bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 312, G390–G404 (2017).
Shiou, S. R. et al. Erythropoietin protects intestinal epithelial barrier function and lowers the incidence of experimental neonatal necrotizing enterocolitis. J. Biol. Chem. 286, 12123–12132 (2011).
Jain, S. K. et al. Amniotic fluid-borne hepatocyte growth factor protects rat pups against experimental necrotizing enterocolitis. Am. J. Physiol. Gastrointest. Liver Physiol. 306, G361–369 (2014).
Di Bella, S. et al. Clostridium difficile Toxins A and B: insights into pathogenic properties and extraintestinal effects. Toxins (Basel). 8, 134 (2016).
Hong, J. et al. The American cockroach peptide periplanetasin-2 blocks clostridium difficile toxin a-induced cell damage and inflammation in the gut. J. Microbiol Biotechnol. 27, 694–700 (2017).
Yun, J., Hwang, J. S. & Lee, D. G. The antifungal activity of the peptide, periplanetasin-2, derived from American cockroach Periplaneta americana. Biochem J. 474, 3027–3043 (2017).
Kim, D. H. et al. The insect peptide CopA3 increases colonic epithelial cell proliferation and mucosal barrier function to prevent inflammatory responses in the gut. J. Biol. Chem. 291, 3209–3223 (2016).
Shrestha, A. et al. A synthetic peptide corresponding to the extracellular loop 2 region of claudin-4 protects against Clostridium perfringens enterotoxin in vitro and in vivo. Infect. Immun. 82, 4778–4788 (2014).
Marin, M. et al. Human cathelicidin improves colonic epithelial defenses against Salmonella typhimurium by modulating bacterial invasion, TLR4 and pro-inflammatory cytokines. Cell Tissue Res 376, 433–442 (2019).
Chen, W. et al. Induction and antiviral activity of human beta-defensin 3 in intestinal cells with picornavirus infection. Acta Virol. 62, 287–293 (2018).
Assis, D. N. & Freedman, S. D. Gastrointestinal disorders in cystic fibrosis. Clin. Chest Med 37, 109–118 (2016).
McHugh, D. R. et al. Linaclotide improves gastrointestinal transit in cystic fibrosis mice by inhibiting sodium/hydrogen exchanger 3. Am. J. Physiol. Gastrointest. Liver Physiol. 315, G868–G878 (2018).
Tanabe, S. et al. Identification of a peptide in enzymatic hydrolyzate of cheese that inhibits ovalbumin permeation in Caco-2 cells. J. Agric Food Chem. 54, 6904–6908 (2006).
Bessette, C. et al. Protective effects of beta-casofensin, a bioactive peptide from bovine beta-casein, against indomethacin-induced intestinal lesions in rats. Mol. Nutr. Food Res 60, 823–833 (2016).
Anthony, A., Pounder, R. E., Dhillon, A. P. & Wakefield, A. J. Similarities between ileal Crohn’s disease and indomethacin experimental jejunal ulcers in the rat. Aliment Pharm. Ther. 14, 241–245 (2000).
Liu, H. et al. Antimicrobial peptide KR-32 alleviates Escherichia coli K88-induced fatty acid malabsorption by improving expression of fatty acid transporter protein 4 (FATP4)1. J. Anim. Sci. 97, 2342–2356 (2019).
Zhang, H. et al. Effects of cathelicidin-derived peptide from reptiles on lipopolysaccharide-induced intestinal inflammation in weaned piglets. Vet. Immunol. Immunopathol. 192, 41–53 (2017).
Luo, X. J. et al. Stimulation of calcitonin gene-related peptide release through targeting capsaicin receptor: a potential strategy for gastric mucosal protection. Dig. Dis. Sci. 58, 320–325 (2013).
Szlachcic, A. et al. New satiety hormone nesfatin-1 protects gastric mucosa against stress-induced injury: mechanistic roles of prostaglandins, nitric oxide, sensory nerves and vanilloid receptors. Peptides 49, 9–20 (2013).
Tache, Y. Brainstem neuropeptides and vagal protection of the gastric mucosal against injury: role of prostaglandins, nitric oxide and calcitonin-gene related peptide in capsaicin afferents. Curr. Med Chem. 19, 35–42 (2012).
Sibilia, V. et al. Characterization of the mechanisms involved in the gastric antisecretory effect of TLQP-21, a vgf-derived peptide, in rats. Amino Acids 42, 1261–1268 (2012).
Sibilia, V. et al. TLQP-21, a VGF-derived peptide, prevents ethanol-induced gastric lesions: insights into its mode of action. Neuroendocrinology 92, 189–197 (2010).
Zhang, Y. et al. Novokinin inhibits gastric acid secretion and protects against alcohol-induced gastric injury in rats. Alcohol 56, 1–8 (2016).
Amorim, M. M. et al. Antiulcer and antiproliferative properties of spent brewer’s yeast peptide extracts for incorporation into foods. Food Funct. 7, 2331–2337 (2016).
Schwarz, P. et al. Hepcidin is localised in gastric parietal cells, regulates acid secretion and is induced by Helicobacter pylori infection. Gut 61, 193–201 (2012).
Nassar, N. N., Schaalan, M. F., Zaki, H. F. & Abdallah, D. M. Octreotide ameliorates gastric lesions in chronically mild stressed rats. World J. Gastroenterol. 17, 1135–1142 (2011).
Bulbul, M., Babygirija, R., Ludwig, K. & Takahashi, T. Central oxytocin attenuates augmented gastric postprandial motility induced by restraint stress in rats. Neurosci. Lett. 479, 302–306 (2010).
Liang, S. et al. Screening and identification of vascular-endothelial-cell-specific binding peptide in gastric cancer. J. Mol. Med (Berl.) 84, 764–773 (2006).
Zhang, J. et al. Targeted radiotherapy with tumor vascular homing trimeric GEBP11 peptide evaluated by multimodality imaging for gastric cancer. J. Control Release 172, 322–329 (2013).
Himaya, S. W., Dewapriya, P. & Kim, S. K. EGFR tyrosine kinase inhibitory peptide attenuates Helicobacter pylori-mediated hyper-proliferation in AGS enteric epithelial cells. Toxicol. Appl Pharm. 269, 205–214 (2013).
Zhang, X. L. et al. The synthetic antimicrobial peptide pexiganan and its nanoparticles (PNPs) exhibit the anti-helicobacter pylori activity in vitro and in vivo. Molecules 20, 3972–3985 (2015).
Esposito, R. et al. Gastric TFF1 expression from acute to chronic helicobacter infection. Front Cell Infect. Microbiol 7, 434 (2017).
Hoffmann, W. TFF2, a MUC6-binding lectin stabilizing the gastric mucus barrier and more (Review). Int J. Oncol. 47, 806–816 (2015).
Gulec Suyen, G., Isbil-Buyukcoskun, N., Cam, B. & Ozluk, K. Effects of centrally injected glucagon-like peptide-2 on gastric mucosal blood flow in rats: possible mechanisms. Peptides 64, 62–66 (2015).
Rotondo, A. et al. Glucagon-like peptide-1 relaxes gastric antrum through nitric oxide in mice. Peptides 32, 60–64 (2011).
Schwarte, L. A. et al. The differential effects of recombinant brain natriuretic peptide, nitroglycerine and dihydralazine on systemic oxygen delivery and gastric mucosal microvascular oxygenation in dogs. Anaesthesia 67, 501–507 (2012).
Takemi, S. et al. The important role of ghrelin on gastric contraction in Suncus murinus. Endocr. J. 64, S11–S14 (2017).
Goswami, C. et al. Motilin stimulates gastric acid secretion in coordination with ghrelin in suncus murinus. PLoS One 10, e0131554 (2015).
Wang, S. H. & Yu, J. Structure-based design for binding peptides in anti-cancer therapy. Biomaterials 156, 1–15 (2018).
Yang, Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J. Clin. Invest 125, 3335–3337 (2015).
Carvajal, L. A. et al. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Science Translational Medicine. 10, eaao3003 (2018).
Carvajal, L. A. et al. Dual inhibition of Mdmx and Mdm2 using an alpha-helical P53 stapled peptide (ALRN-6924) as a novel therapeutic strategy in acute myeloid leukemia. Blood. 130, 795 (2017).
Chang, Y. S. et al. Stapled alpha-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc. Natl Acad. Sci. USA 110, E3445–3454 (2013).
Sun, X. et al. Peptide-based imaging agents for cancer detection. Adv. Drug Deliv. Rev. 110-111, 38–51 (2017).
Deutscher, S. L. Phage display in molecular imaging and diagnosis of cancer. Chem. Rev. 110, 3196–3211 (2010).
Zhao, N., Qin, Y., Liu, H. & Cheng, Z. Tumor-targeting peptides: ligands for molecular imaging and therapy. Anticancer Agents Med Chem. 18, 74–86 (2018).
Xiao, Y. F. et al. Peptide-based treatment: a promising cancer therapy. J. Immunol. Res 2015, 761820 (2015).
Reubi, J. C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 24, 389–427 (2003).
Xu, C. & Zhang, H. Somatostatin receptor based imaging and radionuclide therapy. Biomed. Res Int 2015, 917968 (2015).
Maxwell, J. E. & Howe, J. R. Imaging in neuroendocrine tumors: an update for the clinician. Int J. Endocr. Oncol. 2, 159–168 (2015).
Gao, R. et al. Clinical Value of (99m)Tc-3PRGD2 SPECT/CT in Differentiated Thyroid Carcinoma with Negative (131)I Whole-Body Scan and Elevated Thyroglobulin Level. Sci. Rep. 8, 473 (2018).
Strosberg, J. et al. Phase 3 Trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med 376, 125–135 (2017).
Tagawa, S. T. et al. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177) Lu-J591) for metastatic castration-resistant prostate cancer. Cancer 125, 2561–2569 (2019).
Escala Cornejo, R. A. et al. Large cell neuroendocrine carcinoma of the lung with atypical evolution and a remarkable response to lutetium Lu 177 dotatate. Ann. Nucl. Med 32, 568–572 (2018).
Hagimori, M., Fuchigami, Y. & Kawakami, S. Peptide-based cancer-targeted DDS and molecular imaging. Chem. Pharm. Bull. (Tokyo) 65, 618–624 (2017).
Engel, J. B. et al. Targeting of peptide cytotoxins to LHRH receptors for treatment of cancer. Curr. Drug Targets 17, 488–494 (2016).
Chen, Y., Wu, J. J. & Huang, L. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol. Ther. 18, 828–834 (2010).
Ruoslahti, E. Tumor penetrating peptides for improved drug delivery. Adv. Drug Deliv. Rev. 110-111, 3–12 (2017).
Kotsakis, A. et al. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. Lung Cancer 86, 59–66 (2014).
Mahdavi, M. & Moreau, V. In silico designing breast cancer peptide vaccine for binding to MHC class I and II: A molecular docking study. Comput Biol. Chem. 65, 110–116 (2016).
Kumai, T., Kobayashi, H., Harabuchi, Y. & Celis, E. Peptide vaccines in cancer-old concept revisited. Curr. Opin. Immunol. 45, 1–7 (2017).
Guidotti, G., Brambilla, L. & Rossi, D. Cell-penetrating peptides: from basic research to clinics. Trends Pharm. Sci. 38, 406–424 (2017).
Hill, M. D. et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet 395, 878–887 (2020).
Li, J. et al. Cytomembrane infused polymer accelerating delivery of myelin antigen peptide to treat experimental autoimmune encephalomyelitis. Acs Nano 12, 11579–11590 (2018).
Tsoras, A. N. & Champion, J. A. Cross-linked peptide nanoclusters for delivery of oncofetal antigen as a cancer vaccine. Bioconjug Chem. 29, 776–785 (2018).
Boohaker, R. J. et al. Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction. Cancer Lett. 434, 11–21 (2018).
Zhou, K. et al. Structure-based derivation and intramolecular cyclization of peptide inhibitors from PD-1/PD-L1 complex interface as immune checkpoint blockade for breast cancer immunotherapy. Biophys. Chem. 253, 106213 (2019).
Abbas, A. B. et al. Design and synthesis of A PD-1 binding peptide and evaluation of its anti-tumor activity. Int J Mol Sci. 20, 572 (2019).
Sasikumar, P. G. et al. A rationally designed peptide antagonist of the PD-1 signaling pathway as an immunomodulatory agent for cancer therapy. Mol. Cancer Ther. 18, 1081–1091 (2019).
Mahadevappa, R., Ma, R. & Kwok, H. F. Venom peptides: improving specificity in cancer therapy. Trends Cancer 3, 611–614 (2017).
Okada, M., Ortiz, E., Corzo, G. & Possani, L. D. Pore-forming spider venom peptides show cytotoxicity to hyperpolarized cancer cells expressing K+ channels: A lentiviral vector approach. PLoS One 14, e0215391 (2019).
Zhang, Q. Y. et al. Antimicrobial peptides: mechanism of action, activity and clinical potential. Mil. Med Res 8, 48 (2021).
Jin, G. & Weinberg, A. Human antimicrobial peptides and cancer. Semin Cell Dev. Biol. 88, 156–162 (2019).
Strzelecka, P. et al. Simplified, serine-rich theta-defensin analogues as antitumour peptides. Chem. Biol. Drug Des. 90, 52–63 (2017).
Aronson, M. R. et al. Lipopeptisomes: anticancer peptide-assembled particles for fusolytic oncotherapy. Acta Biomater. 80, 269–277 (2018).
Howard, C. R. & Fletcher, N. F. Emerging virus diseases: can we ever expect the unexpected? Emerg Microbes Infec. 1, e46 (2012).
Rider, T. H. et al. Broad-Spectrum Antiviral Therapeutics. Plos One. 6, e22572 (2011).
Agarwal, G. & Gabrani, R. Antiviral Peptides: Identification and Validation. Int J Pept Res Ther, 18, 1–20 (2020).
Boas, L. C. P. V. et al. Antiviral peptides as promising therapeutic drugs. Cell Mol. Life Sci. 76, 3525–3542 (2019).
Kaconis, Y. et al. A new and promising therapeutic approach against gram-negative sepsis based on the antimicrobial peptide Aspidasept (R) and its derivatives. Infection 41, S15–S15 (2013).
Chew, M. F., Poh, K. S. & Poh, C. L. Peptides as therapeutic agents for dengue virus. Int J. Med Sci. 14, 1342–1359 (2017).
Su, X. et al. Protein- and peptide-based virus inactivators: inactivating viruses before their entry into cells. Front Microbiol 11, 1063 (2020).
Teissier, E., Penin, F. & Pecheur, E. I. Targeting cell entry of enveloped viruses as an antiviral strategy. Molecules 16, 221–250 (2011).
Perry, C. M. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. Drugs 72, 619–641 (2012).
Garnock-Jones, K. P. Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection. Drugs 72, 2431–2456 (2012).
Divyashree, M. et al. Clinical applications of antimicrobial peptides (AMPs): where do we stand now? Protein Pept. Lett. 27, 120–134 (2020).
Bogomolov, P. et al. A proof-of-concept Phase IIa clinical trial to treat chronic HBV/HDV with the entry inhibitor myrcludex B. Hepatology 64, 121a–121a (2016).
Loglio, A. et al. Myrcludex monotherapy in compensated cirrhotics with delta hepatitis: safety and effectiveness beyond two years of treatment in a real-life setting. Hepatology 72, 624a–624a (2020).
Wedemeyer, H. et al. Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. J. Hepatol. 70, E81–E81 (2019).
Badani, H. et al. Mechanism of action of flufirvitide, a peptide inhibitor of influenza virus infection. Biophys. J. 106, 707a–707a (2014).
Skalickova, S. et al. Perspective of use of antiviral peptides against influenza. Virus Viruses-Basel. 7, 5428–5442 (2015).
Yu, D. et al. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor. J. Biol. Chem. 293, 12703–12718 (2018).
Li, L. et al. Efficacy, stability, and biosafety of sifuvirtide gel as a microbicide candidate against HIV-1. PLoS One 7, e37381 (2012).
Yao, X. et al. Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide. J. Biol. Chem. 287, 6788–6796 (2012).
Phelan, A. L., Katz, R. & Gostin, L. O. The novel coronavirus originating in wuhan, China: challenges for global health governance. JAMA 323, 709–710 (2020).
Xia, S. et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res 30, 343–355 (2020).
Jiang, S. Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. Nature 579, 321 (2020).
Ledford, H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature 582, 469 (2020).
Pulla, P. India expands use of controversial drug for coronavirus despite safety concerns. Nature, Epub ahead of print (2020).
Nelde, A. et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol, 22, 74–85 (2020).
Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565–574 (2020).
Wu, F. et al. Author Correction: A new coronavirus associated with human respiratory disease in China. Nature 580, E7 (2020).
Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
Andersen, K. G. et al. The proximal origin of SARS-CoV-2. Nat. Med 26, 450–452 (2020).
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med 383, 2603–2615 (2020).
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med 384, 403–416 (2021).
Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99–111 (2021).
Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187–2201 (2021).
Xia, S. et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect Dis, 22, 196–208 (2021).
Sapkal, G. N. et al. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2. J Travel Med. 28, taab051 (2021).
Topuzogullari, M. et al. An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19. Turk. J. Biol. 44, 215–227 (2020).
Mahdavi, M., Moreau, V. & Kheirollahi, M. Identification of B and T cell epitope based peptide vaccine from IGF-1 receptor in breast cancer. J. Mol. Graph Model 75, 316–321 (2017).
Yasmin, T. & Nabi, A. H. M. N. B and T cell epitope-based peptides predicted from evolutionarily conserved and whole protein sequences of Ebola virus as vaccine targets. Scand. J. Immunol. 83, 321–337 (2016).
Lin, L. et al. Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2. Virus Res 288, 198082 (2020).
Chakraborty, C. et al. Immunoinformatics approach for the identification and characterization of T Cell and B cell epitopes towards the peptide-based vaccine against SARS-CoV-2. Arch. Med. Res. 52, 362–370 (2021).
Bhattacharya, M. et al. Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach. J. Med Virol. 92, 618–631 (2020).
Waqas, M. et al. Determine the potential epitope based peptide vaccine against novel SARS-CoV-2 targeting structural proteins using immunoinformatics approaches. Front. in Mol. Biosci. 7, 227 (2020).
Kalita, P., Padhi, A. K., Zhang, K. Y. J. & Tripathi, T. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. Micro. Pathog. 145, 104236 (2020).
Lim, H. X. et al. Development of multi-epitope peptide-based vaccines against SARS-CoV-2. Biomed. J. 44, 18–30 (2021).
Alam, A. et al. Design of an epitope-based peptide vaccine against the SARS-CoV-2: a vaccine-informatics approach. Brief. Bioinforma. 22, 1309–1323 (2021).
Herst, C. V. et al. An effective CTL peptide vaccine for Ebola Zaire Based on Survivors’ CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design. Vaccine 38, 4464–4475 (2020).
Bhattacharjee, S. Toward COVID-19 Therapeutics: a viewpoint from the nonprotein amino acid based synthetic peptide design approach. ACS Chem Neurosci, 11, 3701–3703 (2020).
Kabra, R. & Singh, S. Evolutionary artificial intelligence based peptide discoveries for effective Covid-19 therapeutics. Biochim Biophys. Acta Mol. Basis Dis. 1867, 165978 (2020).
Sahu, B. et al. Design and in-silico screening of Peptide Nucleic Acid (PNA) inspired novel pronucleotide scaffolds targeting COVID-19. Curr Comput Aided Drug Des, 18, 26–40 (2020).
Zhao, Q. Y. et al. Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates. Chem. Commun. 57, 1474–1477 (2021).
Knop, F. K., Bronden, A. & Vilsboll, T. Exenatide: pharmacokinetics, clinical use, and future directions. Expert Opin. Pharmacother. 18, 555–571 (2017).
Ladenheim, E. E. Liraglutide and obesity: a review of the data so far. Drug Des., Dev. Ther. 9, 1867–1875 (2015).
Petersen, A. B., Knop, F. K. & Christensen, M. Lixisenatide for the treatment of type 2 diabetes. Drugs today 49, 537–553 (2013).
Bronden, A., Naver, S. V., Knop, F. K. & Christensen, M. Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opin. drug Metab. Toxicol. 11, 1493–1503 (2015).
Jendle, J. et al. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes/Metab. Res. Rev. 32, 776–790 (2016).
Pratley, R. et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 394, 39–50 (2019).
Kim, E. S. & Keam, S. J. Teduglutide: a review in short bowel syndrome. Drugs 77, 345–352 (2017).
Love, B. L., Johnson, A. & Smith, L. S. Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome. Am. J. Health-Syst. Pharm.: AJHP: Off. J. Am. Soc. Health-Syst. Pharmacists 71, 1081–1091 (2014).
Younk, L. M., Mikeladze, M. & Davis, S. N. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin. Pharmacother. 12, 1439–1451 (2011).
Kirby, R. S., Fitzpatrick, J. M. & Clarke, N. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int 104, 1580–1584 (2009).
Sonesson, A. & Rasmussen, B. B. In vitro and in vivo human metabolism of degarelix, a gonadotropin-releasing hormone receptor blocker. Drug Metab. disposition: Biol. fate Chem. 41, 1339–1346 (2013).
Mushtaq, A. et al. Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. Crit. Rev. Oncol./Hematol. 125, 1–11 (2018).
Meyers, P. A. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev. anticancer Ther. 9, 1035–1049 (2009).
Keijzers, G. B. Aviptadil (Senatek). Curr. Opin. investigational drugs 2, 545–549 (2001).
Wisniewski, K. Design of oxytocin analogs. Methods Mol. Biol. 2001, 235–271 (2019).
Thirunarayanan, N., Raaka, B. M. & Gershengorn, M. C. Taltirelin is a superagonist at the human thyrotropin-releasing hormone receptor. Front Endocrinol. (Lausanne) 3, 120 (2012).
Dhillon, S. & Keam, S. J. Bremelanotide: first approval. Drugs 79, 1599–1606 (2019).
Minisola, S. et al. Update on the safety and efficacy of teriparatide in the treatment of osteoporosis. Ther. Adv. Musculoskelet. Dis. 11, 1759720X19877994 (2019).
Bhattacharyya, S., Pal, S. & Chattopadhyay, N. Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide. Biochem Pharmacol. 166, 185–191 (2019).
DeMicco, M. et al. Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation. Therapeutic Adv. Gastroenterol. 10, 837–851 (2017).
O’Connor, C. M. et al. Effect of nesiritide in patients with acute decompensated heart failure. N. Engl. J. Med 365, 32–43 (2011).
Jadhav, A. P. & Sadaka, F. G. Angiotensin II in septic shock. Am. J. Emerg. Med 37, 1169–1174 (2019).
Jeon, J., Lee, Y. J. & Lee, S. Y. Effect of icatibant on angiotensin-converting enzyme inhibitor-induced angioedema: a meta-analysis of randomized controlled trials. J. Clin. Pharm. therapeutics. 44, 685–692 (2019).
Pu, J. et al. Development of protein- and peptide-based HIV entry inhibitors targeting gp120 or gp41. Viruses. 11, 705 (2019).
Grunfeld, C., Dritselis, A. & Kirkpatrick, P. Tesamorelin. Nat. Rev. Drug Disco. 10, 95–96 (2011).
Williams, J. A., Day, M. & Heavner, J. E. Ziconotide: an update and review. Expert Opin. Pharmacother. 9, 1575–1583 (2008).
Neunert, C. E. & Rose, M. J. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice. Blood Adv. 3, 1907–1915 (2019).
Schmid, H. Peginesatide for the treatment of renal disease-induced anemia. Expert Opin. Pharmacother. 14, 937–948 (2013).
Piehl, E. & Fernandez-Bustamante, A. Lucinactant for the treatment of respiratory distress syndrome in neonates. Drugs today 48, 587–593 (2012).
Hamano, N., Komaba, H. & Fukagawa, M. Etelcalcetide for the treatment of secondary hyperparathyroidism. Expert Opin. Pharmacother. 18, 529–534 (2017).
Minder, E. I., Barman-Aksoezen, J. & Schneider-Yin, X. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clin. pharmacokinetics 56, 815–823 (2017).
Wildemberg, L. E. & Gadelha, M. R. Pasireotide for the treatment of acromegaly. Expert Opin. Pharmacother. 17, 579–588 (2016).
Lutetium lu. 177 dotatate (Lutathera) for gastroenteropancreatic neuroendocrine tumors. Med Lett Drugs Ther. 60, e152–e153, (2018).
Lutetium Lu. 177 Dotatate Approved by FDA. Cancer Discov. 8, OF2, (2018).
Evangelista, L. et al. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: a review. Clin. Imaging 67, 113–116 (2020).
Moyade, P. & Vinjamuri, S. The heart matters: a review of incidental cardiac uptake on Ga-68 DOTA peptide PET-CT scans. Nucl. Med Commun. 40, 1081–1085 (2019).
Haws, R. et al. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Diabetes Obes Metab, 22, 2133–2140 (2020).
Kamermans, A. et al. Setmelanotide, a novel, selective melanocortin receptor-4 agonist exerts anti-inflammatory actions in astrocytes and promotes an anti-inflammatory macrophage phenotype. Front Immunol. 10, 2312 (2019).
Craig, C. M. et al. Efficacy and pharmacokinetics of subcutaneous exendin (9-39) in patients with post-bariatric hypoglycaemia. Diabetes Obes. Metab. 20, 352–361 (2018).
Schuster, N. M. & Rapoport, A. M. Calcitonin gene-related peptide-targeted therapies for migraine and cluster headache: a review. Clin. Neuropharmacol. 40, 169–174 (2017).
Panickar, K. S. Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema. Curr. Opin. Mol. Ther. 12, 780–789 (2010).
Izquierdo, A. G., Crujeiras, A. B., Casanueva, F. F. & Carreira, M. C. Leptin, Obesity, and leptin resistance: where are we 25 years later? Nutrients. 11, 2704 (2019).
Sjogren, M. H. Thymalfasin: an immune system enhancer for the treatment of liver disease. J. Gastroenterol. Hepatol. 19, S69–72 (2004).
Nguyen, T. T. et al. Expression of active matrix metalloproteinase-9 as a likely contributor to the clinical failure of aclerastide in treatment of diabetic foot ulcers. Eur. J. Pharmacol. 834, 77–83 (2018).
Rodgers, K. E., Bolton, L. L., Verco, S. & diZerega, G. S. NorLeu(3)-Angiotensin (1-7) [DSC127] as a Therapy for the Healing of Diabetic Foot Ulcers. Adv. wound care 4, 339–345 (2015).
Cohen-Barak, O. et al. Assessment of the pharmacokinetics, pharmacodynamics, and safety of single doses of TV-1106, a long-acting growth hormone, in healthy Japanese and Caucasian subjects. Clin. Pharm. Drug Dev. 6, 331–342 (2017).
Temel, J. S. et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 17, 519–531 (2016).
Rocha-Lima, C. M. et al. A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan. Cancer Chemother. Pharm. 74, 479–486 (2014).
Hirose, T. et al. Open-label, randomized study comparing basal insulin peglispro and insulin glargine, in combination with oral antihyperglycemic medications, in insulin-naive Asian patients with type 2 diabetes. J. Diabetes Investig. 9, 100–107 (2018).
Lin, T. C. & Hsiao, M. Ghrelin and cancer progression. Biochim Biophys. Acta Rev. Cancer 1868, 51–57 (2017).
Laterre, P. F. et al. Effect of selepressin vs placebo on ventilator- and vasopressor-free days in patients with septic shock: the SEPSIS-ACT randomized clinical trial. JAMA, 322, 1476-1485 (2019).
Johannsson, G. et al. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial. Eur. J. Endocrinol. 178, 491–499 (2018).
Dong, J. Z. et al. Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes. Diabetes Obes. Metab. 13, 19–25 (2011).
Sosne, G. & Ousler, G. W. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clin. Ophthalmol. 9, 877–884 (2015).
Frias, J. P. et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392, 2180–2193 (2018).
Anker, S. D. et al. Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur. Heart J. 36, 715–723 (2015).
Cales, P. et al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N. Engl. J. Med 344, 23–28 (2001).
Lorget, F. et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am. J. Hum. Genet 91, 1108–1114 (2012).
Emons, G. et al. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5). Gynecol. Oncol. 133, 427–432 (2014).
Savage, P. D. et al. Phase II trial of angiotensin-(1-7) for the treatment of patients with metastatic sarcoma. Sarcoma 2016, 4592768 (2016).
Escudero-Castellanos, A. et al. Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer. Nucl. Med Commun. 40, 278–286 (2019).
Lucas, X. Clinical use of deslorelin (GnRH agonist) in companion animals: a review. Reprod. Domest. Anim. 49, 64–71 (2014).
Sekar, R., Singh, K., Arokiaraj, A. W. & Chow, B. K. Pharmacological actions of glucagon-like peptide-1, gastric inhibitory polypeptide, and glucagon. Int Rev. Cell Mol. Biol. 326, 279–341 (2016).
Hewitt, D. J. et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 31, 712–722 (2011).
Recober, A. & Russo, A. F. Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment. IDrugs 10, 566–574 (2007).
Rabiee, A. et al. Pancreatic polypeptide administration enhances insulin sensitivity and reduces the insulin requirement of patients on insulin pump therapy. J. Diabetes Sci. Technol. 5, 1521–1528 (2011).
Ukkola, O. H. et al. High serum fasting peptide YY (3-36) is associated with obesity-associated insulin resistance and type 2 diabetes. Regul. Pept. 170, 38–42 (2011).
Shailubhai, K. et al. Phase II clinical evaluation of SP-304, a guanylate cyclase-c agonist, for treatment of chronic constipation: 1322. 105, S487–S488, (2010).
Koch, L. Pharmacotherapy: somatoprim versus octreotide in acromegaly. Nat. Rev. Endocrinol. 8, 66 (2011).
de Schepper, J. et al. Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics. Eur. J. Endocrinol. 165, 401–409 (2011).
Nielsen, V. E. et al. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Arch. Intern Med 166, 1476–1482 (2006).
Tejeda, M. et al. Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models. Anticancer Res 26, 3477–3483 (2006).
Ding, L. et al. BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus. Pharm. Res 122, 130–139 (2017).
Walter, M. et al. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care 32, 2036–2040 (2009).